ALX Oncology Holdings Inc expected to post a loss of 63  cents a share - Earnings Preview

ALX Oncology Holdings

08/08/2022 13:31

* ALX Oncology Holdings Inc  ALXO.OQ   ALXO.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for ALX Oncology
Holdings Inc
is for a loss of 63 cents per share. For the same quarter last
year, the company reported a loss of 40 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $45.5​, above​ its last closing price of $11.47.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.71       -0.71      -0.60     Beat    15.8
 Dec. 31 2022  -0.62       -0.62      -0.70     Missed  -13.1
 Sep. 30 2021  -0.47       -0.48      -0.61     Missed  -28.2​
 Jun. 30 2021  -0.43       -0.43      -0.40     Beat    6.5
 ​​Mar.        -0.41       -0.41      -0.35     Beat    15
 31 2021                                                
 Dec. 31 2020  -0.30       -0.35      -0.48     Missed  -35.7​
 Sep. 30 2020  -0.36       -0.36      -0.36     Met     0.1
 Jun. 30 2020  -0.33       -0.33      -3.38     Missed  -915
 This summary was machine generated August 8 at 12:31 GMT.  All
figures in US dollars  unless otherwise stated